Skip to content
zameds

Cefotaxime (Cefotaxime Fresenius)

Cefotaxime

Fresenius Kabi Manufacturing SA (Pty) Ltd

Every registration of this product has been cancelled.

S4

Registration

Applicant
Fresenius Kabi Manufacturing SA (Pty) Ltd
Registrations
1
Schedule source
Consolidated Schedules 06 July 2026

Variants

ProductStrength and formRegistrationStatusScheduleLeaflets
Cefotaxime fresenius 2,0 g

EACH VIAL CONTAINS CEFOTAXIME SODIUM EQUIVALENT TO CEFOTAXIME 2000,0 mg

2,0 g37057837/20.1.1/0578CancelledS4None

Regulatory status

Where S4 sits on the scale

Prescription-only medicine.

Schedule 4 covers most ordinary prescription medicines. You need a prescription from an authorised prescriber, such as a doctor or dentist, and a pharmacist dispenses it. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.

Schedule S4, matched to the Consolidated Schedules by ingredient, confidence high.

Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.

Consolidated Schedules listings for Cefotaxime sodium equivalent to cefotaxime

  • S4: Cefotaxime

    Consolidated Schedules 06 July 2026, line 5717

Pharmacological class: Broad and medium spectrum antibiotics. (class 20.1.1)

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

C16H17N5O7S2455.50 g/mol

(6R,7R)-3-(Acetyloxymethyl)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

Drag to rotate. Structure from PubChem CID 5742673.

SAHPRA documents

SAHPRA has not published a professional information or patient information leaflet for this product.

Background

Loading...
Loading Wikipedia summary

Research articles

Loading...
Loading PubMed articles